O
CGEM icon

OrbiMed’s Cullinan Oncology CGEM Stock Holding History

OrbiMed’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-243,006
Closed -$3.45M – 136
2026
Q1 		$3.45M Sell
243,006
-27,000
-10% -$347K 0.07% 100
2025
Q4 		$2.79M Sell
270,006
-1,653,849
-86% -$14.9M 0.06% 95
2025
Q3 		$11.4M Hold
1,923,855
– – 0.27% 72
2025
Q2 		$14.5M Hold
1,923,855
– – 0.36% 50
2025
Q1 		$14.6M Sell
1,923,855
-18,700
-1% -$179K 0.35% 52
2024
Q4 		$23.7M Buy
1,942,555
+872,500
+82% +$12.5M 0.49% 46
2024
Q3 		$17.9M Sell
1,070,055
-77,600
-7% -$1.38M 0.33% 68
2024
Q2 		$20M Buy
1,147,655
+630,049
+122% +$13.4M 0.4% 61
2024
Q1 		$8.82M Sell
517,606
-27,242
-5% -$421K 0.16% 83
2023
Q4 		$5.55M Hold
544,848
– – 0.11% 89
2023
Q3 		$4.93M Hold
544,848
– – 0.1% 99
2023
Q2 		$5.86M Sell
544,848
-60,539
-10% -$643K 0.11% 98
2023
Q1 		$6.19M Sell
605,387
-31,900
-5% -$352K 0.12% 99
2022
Q4 		$6.72M Hold
637,287
– – 0.13% 84
2022
Q3 		$8.17M Sell
637,287
-33,500
-5% -$451K 0.15% 90
2022
Q2 		$8.6M Hold
670,787
– – 0.16% 98
2022
Q1 		$7.02M Sell
670,787
-134,254
-17% -$1.81M 0.11% 110
2021
Q4 		$12.4M Sell
805,041
-341,104
-30% -$6.8M 0.16% 109
2021
Q3 		$25.9M Hold
1,146,145
– – 0.28% 85
2021
Q2 		$29.5M Hold
1,146,145
– – 0.3% 77
2021
Q1 		$47.8M Buy
+1,146,145
New +$46.5M 0.45% 64

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

OrbiMed's CGEM Position: Q2 2026 in Review

OrbiMed sold out of Cullinan Oncology (CGEM) in Q2 2026, closing a stake of 243,006 shares — an estimated $3.45M sold.

OrbiMed first reported a position in CGEM in Q1 2021 and held it in 21 quarters. The position peaked at $47.8M in Q1 2021. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • OrbiMed reported no remaining Cullinan Oncology position as of Q2 2026 after selling out during the quarter.
  • OrbiMed sold 243,006 Cullinan Oncology shares in Q2 2026, an estimated $3.45M.
  • OrbiMed first reported a position in Cullinan Oncology in Q1 2021 and held it in 21 quarters.
  • OrbiMed's Cullinan Oncology position peaked at $47.8M in Q1 2021.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.